Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CES1 Genetic Variation and Methylphenidate in ADHD
NCT03781752Phase 4Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2018
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Icahn School of Medicine at Mount Sinai. Started Mar 2018; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03781752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781752.